The Quantellect read.As of Nov 19, 2026, 5 active firms cover Prime Medicine, Inc. Common Stock: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $7.00 to $11.00, a moderate spread. The average target of $8.75 sits 128% above the current $3.83. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-0.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.75
+128.3% upside
Average target across 4 active firms as of Nov 19, 2026 vs $3.83 current
Highest Target$11.00
Average Target$8.75
Lowest Target$7.00
Detailed analyst forecasts for PRME
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate PRME a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRME EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.28 – $-0.19 · 6 analysts · -21% YoY
Next period, 6 analysts expect Prime Medicine, Inc. Common Stock to earn $-0.22 a share (range $-0.28 – $-0.19), versus $-0.28 a year earlier. Full-year consensus is $-0.92, growing to $-0.81 the year after.
REVENUE · NEXT QUARTER
$1.4M
Range $0 – $2.5M · 6 analysts · +69% YoY
Revenue is expected to reach $1.4M (range $0 – $2.5M), +69.4% year-over-year. Full-year consensus is $11.6M, rising to $13.7M next year.
Top analysts covering Prime Medicine, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRME.
#1
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$6.00+56.5% to target
Overall win rate
51%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #104
Buy
$9.00+134.8% to target
Overall win rate
43%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Buy
$7.00+82.6% to target
Overall win rate
41%
+ Follow
#4
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$8.00+108.7% to target
Overall win rate
50%
+ Follow
#5
Terence Flynn
Morgan Stanley · Rank #222
Neutral
No targeton PRME
Overall win rate
36%
+ Follow
PRME stock forecast FAQ
What is PRME's average 12-month price target?+
The 4 active firms with a live target average $8.75 for Prime Medicine, Inc. Common Stock over the next 12 months, ranging from a $11.00 high to a $7.00 low, as of Nov 19, 2026.
Is PRME stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRME?+
The Street-high target is $11.00 (Oppenheimer), and the Street-low is $7.00 (Chardan Capital). The average of all 4 active-firm targets is $8.75.
How many active Wall Street firms cover PRME?+
5 active firms have a recognized rating on Prime Medicine, Inc. Common Stock as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRME?+
Among analysts who currently cover PRME, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $6.00 target.
What is Prime Medicine, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.28 – $-0.19) across 6 analysts. Full-year EPS is projected at $-0.92, rising to $-0.81 the following year.
How much revenue is Prime Medicine, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $1.4M (range $0 – $2.5M). Full-year revenue is projected at $11.6M, growing to $13.7M next year.
Have analysts been upgrading or downgrading PRME lately?+
As of Nov 19, 2026, 5 of 5 active firms rate PRME a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.